Literature DB >> 21091979

The association between renal cell carcinoma and multiple myeloma: insights from population-based data.

Rohit P Ojha1, Eva L Evans, Martha J Felini, Karan P Singh, Raymond Thertulien.   

Abstract

OBJECTIVE: • To evaluate the hypothesis of an association between renal cell carcinoma and multiple myeloma. PATIENTS AND METHODS: • Data from nine population-based registries in the Surveillance, Epidemiology and End Results programme were used to evaluate two separate cohorts of patients diagnosed between 1973 and 2006: patients diagnosed with renal cell carcinoma as a primary malignancy (n= 57,190) and patients diagnosed with multiple myeloma as a primary malignancy (n= 34,156). • We estimated standardized incidence ratios (SIRs) with corresponding 95% confidence intervals (CIs) by dividing the number of observed cases of multiple myeloma within the renal cell carcinoma cohort and the number of renal cell carcinoma cases within the multiple myeloma cohort by the number of expected cases for each malignancy in the US general population.
RESULTS: • The renal cell carcinoma cohort yielded 88 multiple myeloma cases during 293,511 person-years of follow up. Patients with renal cell carcinoma had a higher relative risk of multiple myeloma than the general population (SIR = 1.51, 95% CI 1.21-1.85). • The multiple myeloma cohort yielded 69 renal cell carcinoma cases during 100,804 person-years of follow up. Patients with multiple myeloma had a higher relative risk of renal cell carcinoma than the general population (SIR = 1.89, 95% CI 1.47-2.40).
CONCLUSION: • Our analyses revealed a bidirectional association between renal cell carcinoma and multiple myeloma, which typically indicates shared risk factors.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2010        PMID: 21091979     DOI: 10.1111/j.1464-410X.2010.09892.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

1.  A coincidence of renal cell carcinoma and hematological malignancies.

Authors:  Gokhan Sargın; Irfan Yavasoglu; Firuzan Kacar Doger; Gurhan Kadikoylu; Zahit Bolaman
Journal:  Med Oncol       Date:  2012-07-29       Impact factor: 3.064

2.  Plasmablastic multiple myeloma following clear cell renal cell carcinoma.

Authors:  Somanath Padhi; Sudhagar Mokkappan; Renu G' Boy Varghese; Ilangovan Veerappan
Journal:  BMJ Case Rep       Date:  2014-08-06

Review 3.  Coexistence of multiple myeloma and clear cell renal cell carcinoma: a case report and review of literature.

Authors:  Gaixiang Xu; Min Yang; Jian Huang; Jie Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

4.  Renal cell carcinoma and plasma cell myeloma: Unique association and clinical implications.

Authors:  Somanath Padhi; Pradyumna Kumar Sahoo; Debashis Banerjee; Rabindra Nath Ghosh
Journal:  Urol Ann       Date:  2014-07

5.  Renal cell carcinoma and plasma cell myeloma: Coincidence or true association?

Authors:  Muhammed Mubarak
Journal:  Urol Ann       Date:  2014-07

6.  Collision Tumor With Renal Cell Carcinoma and Plasmacytoma: Further Evidence of a Renal Cell and Plasma Cell Neoplasm Relationship?

Authors:  Sean W Berquist; Abd-Elrahman Said Hassan; Olga Miakicheva; Catherine Dufour; Zachary Hamilton; Ahmed Shabaik; Ithaar H Derweesh
Journal:  Urol Case Rep       Date:  2016-04-01

7.  Refractory primary extramedullary plasmacytoma in kidney: a case report.

Authors:  Wenjie Niu; Lili Zhang; Yuhai Wu; Kai Li; Lixia Sun; Hong Ji; Bing Zhang
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

8.  Renal cell carcinoma concomitant with multiple myeloma.

Authors:  Anubhav Narwal; Prashant Ramteke; Lalit Kumar; Saumyaranjan Mallick
Journal:  J Pathol Transl Med       Date:  2022-03-11

9.  A patient with Multiple myeloma and Renal cell carcinoma.

Authors:  Farhad Shahi; Marziye Ghalamkari; Mehrzad Mirzania; Mahdi Khatuni
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-01-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.